The impact of diabetes mellitus on the survival of patients with acromegaly

Chiou Wen-Ko, Chen Szu-Ta, Liu Feng-Hsuan, Chang Chen-Nen, Wang Ming-Hsu, Lin Jen-Der

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: An increased risk of mortality in patients with uncontrolled acromegaly has been reported in several studies. We aimed to assess the impact of co-morbidities on the survival of patients with acromegaly after long-term treatment and follow-up. Materials and methods: A retrospective analysis was performed for 285 patients with active acromegaly, who were admitted to the Chang Gung Memorial Hospital, Taiwan between 1978 and 2012. Of these patients, 106 (37.2%) were diagnosed with diabetes mellitus (DM). During the follow-up period, 21 cases of histological proved malignant in acromegalic patients, and DM with acromegaly had a higher incidence of malignancy (13.2% vs. 3.8%; p < 0.01). The 5-, 10-, and 20-year survival rates were 93.1%, 86.9%, and 84.7% for the DM group, respectively, and 96.5%, 96.5%, and 96.5% for the non-DM group, respectively. After a mean follow-up of 15.1 ± 0.6 years, age, DM, coronary heart disease, and malignancy were found to be significant factors of mortality. Control of growth hormone and IGF-1 levels also conferred a marginal survival benefit. Conclusions: DM and malignancy significantly influence the survival of patients with acromegaly; thus, these patients need close follow-up and appropriate therapy.

Original languageEnglish
Pages (from-to)501-506
Number of pages6
JournalEndokrynologia Polska
Volume67
Issue number5
DOIs
Publication statusPublished - Jan 1 2016
Externally publishedYes

Fingerprint

Acromegaly
Diabetes Mellitus
Survival
Neoplasms
Mortality
Insulin-Like Growth Factor I
Taiwan
Growth Hormone
Coronary Disease
Survival Rate
Morbidity
Incidence
Therapeutics

Keywords

  • Co-morbidities
  • IGF-1
  • Malignancy

ASJC Scopus subject areas

  • Endocrinology

Cite this

The impact of diabetes mellitus on the survival of patients with acromegaly. / Wen-Ko, Chiou; Szu-Ta, Chen; Feng-Hsuan, Liu; Chen-Nen, Chang; Ming-Hsu, Wang; Jen-Der, Lin.

In: Endokrynologia Polska, Vol. 67, No. 5, 01.01.2016, p. 501-506.

Research output: Contribution to journalArticle

Wen-Ko, C, Szu-Ta, C, Feng-Hsuan, L, Chen-Nen, C, Ming-Hsu, W & Jen-Der, L 2016, 'The impact of diabetes mellitus on the survival of patients with acromegaly', Endokrynologia Polska, vol. 67, no. 5, pp. 501-506. https://doi.org/10.5603/EP.a2016.0031
Wen-Ko, Chiou ; Szu-Ta, Chen ; Feng-Hsuan, Liu ; Chen-Nen, Chang ; Ming-Hsu, Wang ; Jen-Der, Lin. / The impact of diabetes mellitus on the survival of patients with acromegaly. In: Endokrynologia Polska. 2016 ; Vol. 67, No. 5. pp. 501-506.
@article{9e790089a55e46bcaab26a2e717b2b4b,
title = "The impact of diabetes mellitus on the survival of patients with acromegaly",
abstract = "Introduction: An increased risk of mortality in patients with uncontrolled acromegaly has been reported in several studies. We aimed to assess the impact of co-morbidities on the survival of patients with acromegaly after long-term treatment and follow-up. Materials and methods: A retrospective analysis was performed for 285 patients with active acromegaly, who were admitted to the Chang Gung Memorial Hospital, Taiwan between 1978 and 2012. Of these patients, 106 (37.2{\%}) were diagnosed with diabetes mellitus (DM). During the follow-up period, 21 cases of histological proved malignant in acromegalic patients, and DM with acromegaly had a higher incidence of malignancy (13.2{\%} vs. 3.8{\%}; p < 0.01). The 5-, 10-, and 20-year survival rates were 93.1{\%}, 86.9{\%}, and 84.7{\%} for the DM group, respectively, and 96.5{\%}, 96.5{\%}, and 96.5{\%} for the non-DM group, respectively. After a mean follow-up of 15.1 ± 0.6 years, age, DM, coronary heart disease, and malignancy were found to be significant factors of mortality. Control of growth hormone and IGF-1 levels also conferred a marginal survival benefit. Conclusions: DM and malignancy significantly influence the survival of patients with acromegaly; thus, these patients need close follow-up and appropriate therapy.",
keywords = "Co-morbidities, IGF-1, Malignancy",
author = "Chiou Wen-Ko and Chen Szu-Ta and Liu Feng-Hsuan and Chang Chen-Nen and Wang Ming-Hsu and Lin Jen-Der",
year = "2016",
month = "1",
day = "1",
doi = "10.5603/EP.a2016.0031",
language = "English",
volume = "67",
pages = "501--506",
journal = "Endokrynologia Polska",
issn = "0423-104X",
publisher = "Via Medica",
number = "5",

}

TY - JOUR

T1 - The impact of diabetes mellitus on the survival of patients with acromegaly

AU - Wen-Ko, Chiou

AU - Szu-Ta, Chen

AU - Feng-Hsuan, Liu

AU - Chen-Nen, Chang

AU - Ming-Hsu, Wang

AU - Jen-Der, Lin

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Introduction: An increased risk of mortality in patients with uncontrolled acromegaly has been reported in several studies. We aimed to assess the impact of co-morbidities on the survival of patients with acromegaly after long-term treatment and follow-up. Materials and methods: A retrospective analysis was performed for 285 patients with active acromegaly, who were admitted to the Chang Gung Memorial Hospital, Taiwan between 1978 and 2012. Of these patients, 106 (37.2%) were diagnosed with diabetes mellitus (DM). During the follow-up period, 21 cases of histological proved malignant in acromegalic patients, and DM with acromegaly had a higher incidence of malignancy (13.2% vs. 3.8%; p < 0.01). The 5-, 10-, and 20-year survival rates were 93.1%, 86.9%, and 84.7% for the DM group, respectively, and 96.5%, 96.5%, and 96.5% for the non-DM group, respectively. After a mean follow-up of 15.1 ± 0.6 years, age, DM, coronary heart disease, and malignancy were found to be significant factors of mortality. Control of growth hormone and IGF-1 levels also conferred a marginal survival benefit. Conclusions: DM and malignancy significantly influence the survival of patients with acromegaly; thus, these patients need close follow-up and appropriate therapy.

AB - Introduction: An increased risk of mortality in patients with uncontrolled acromegaly has been reported in several studies. We aimed to assess the impact of co-morbidities on the survival of patients with acromegaly after long-term treatment and follow-up. Materials and methods: A retrospective analysis was performed for 285 patients with active acromegaly, who were admitted to the Chang Gung Memorial Hospital, Taiwan between 1978 and 2012. Of these patients, 106 (37.2%) were diagnosed with diabetes mellitus (DM). During the follow-up period, 21 cases of histological proved malignant in acromegalic patients, and DM with acromegaly had a higher incidence of malignancy (13.2% vs. 3.8%; p < 0.01). The 5-, 10-, and 20-year survival rates were 93.1%, 86.9%, and 84.7% for the DM group, respectively, and 96.5%, 96.5%, and 96.5% for the non-DM group, respectively. After a mean follow-up of 15.1 ± 0.6 years, age, DM, coronary heart disease, and malignancy were found to be significant factors of mortality. Control of growth hormone and IGF-1 levels also conferred a marginal survival benefit. Conclusions: DM and malignancy significantly influence the survival of patients with acromegaly; thus, these patients need close follow-up and appropriate therapy.

KW - Co-morbidities

KW - IGF-1

KW - Malignancy

UR - http://www.scopus.com/inward/record.url?scp=84994578186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994578186&partnerID=8YFLogxK

U2 - 10.5603/EP.a2016.0031

DO - 10.5603/EP.a2016.0031

M3 - Article

VL - 67

SP - 501

EP - 506

JO - Endokrynologia Polska

JF - Endokrynologia Polska

SN - 0423-104X

IS - 5

ER -